Vaccine Update - Availability of Vaxelis vaccine alternative to Infanrix hexa
Availability of Vaxelis vaccine alternative to Infanrix hexa - 12 January 2022
As part of the current vaccination programme, Vaxelis® will be made available to order via ImmForm from 31st January 2022. Vaxelis® is an alternative hexavalent vaccine to Infanrix hexa® (DTaP/IPV/Hib/HepB) for routine infant primary immunisations scheduled at 8, 12 and 16 weeks of age. Vaxelis protects against the same six diseases as Infanrix hexa® and has been licensed in Europe for more than five years.
Vaxelis® and Infanrix hexa® vaccines are interchangeable, but where possible and if local stock allows, it is preferable that the same DTaP/IPV/Hib/HepB-containing vaccine be used for all three doses of the primary course. However, vaccination should never be delayed because the vaccine used for previous doses is not known or unavailable.
The hexavalent vaccine DTaP/IPV/Hib/HepB PGD national template (version 03.00, valid from 1 September 2021) includes use of both Infanrix hexa® and Vaxelis®.
Ordering controls for Vaxelis® will be in place to balance incoming supply with demand. Customers in England and Wales may order up to 6 packs of Vaxelis® per ImmForm account per week. Customers in Scotland should refer to their local ordering restrictions. Providers should not order more than two weeks’ worth of stock to minimise wastage due to fridge failures.
Further details can be found in the Vaxelis® Summary of Product Characteristics at - Vaxelis suspension for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)
Vaccine supply team